Efficacy of sirolimus-based immunosuppression in patients with hepatocellular carcinoma after liver transplantation
10.3760/cma.j.cn421203-20201201-00404
- VernacularTitle:mTOR抑制剂对预防肝癌肝移植术后肿瘤复发的疗效分析
- Author:
Meixi WANG
1
;
Yuanyuan ZHAO
;
Lai WEI
;
Dong CHEN
;
Jipin JIANG
;
Zhishui CHEN
Author Information
1. 华中科技大学同济医学院附属同济医院器官移植研究所 器官移植教育部重点实验室 国家卫生健康委员会器官移植重点实验室 中国医学科学院器官移植重点实验室，武汉 430030
- Keywords:
Liver transplantation;
Liver cancer;
Calcineurin inhibitor
- From:
Chinese Journal of Organ Transplantation
2021;42(9):529-533
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of sirolimus-based immunosuppressive protocol on tumor recurrence and tumor-free survival after liver transplantation(LT)in hepatocellular carcinoma (HCC)patients.Methods:From January 1, 2016 to December 31, 2018, a total of 114 HCC patients undergoing LT were recruited and divided into two groups of sirolimus(SRL)and tacrolimus. Univariate and multivariant analyses were performed for evaluating the risk factors of recurrence after LT. Tumor-free survival were compared using Cox logistic regression analysis.Results:Tumor recurrence and/or metastasis occurred in 45 patients. Univariate and multivariate regression analysis indicated that sirolimus was an independent protective factor for preventing tumor recurrence( P=0.005, HR=0.38, 95% CI 0.193~0.748). The median tumor-free survival time was 5(4~19)months in tacrolimus group and 23(13~31)months in sirolimus group. No inter-group statistical difference existed in incidence of infection or rejection complications( P>0.05). Conclusions:HCC patients benefit from sirolimus-based immunosuppressive protocol after LT. And sirolimus may reduce tumor recurrence rate and prolong tumor-free survival time.
